Drug Approval | February 14, 2026
FDA nod to Acrotech's new eczema treatment
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The collaboration will center on expanding access to Eastman’s Esmeri technology
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The supplements are made using only vegetarian-sourced ingredients
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
